Alnylam Pulls TV Ad After FDA Crackdown on Drug Commercials (1)

Alnylam Pharmaceuticals Inc. has stopped airing a TV commercial for its new heart medicine, a sign that the Trump administration’s crackdown on the industry’s ubiquitous drug ads is having an impact on the media landscape.

Alnylam was one of many companies to get letters last month from the US Food and Drug Administration calling out what the agency believes are misleading commercials. Most of the letters, sent to companies including AstraZeneca Plc, Bristol Myers Squibb Co. and AbbVie Inc., detail concerns with their online, broadcast and print marketing, ranging from hiring actors who appear too healthy to omitting ...